Head-To-Head Review: Protalix BioTherapeutics (NYSE:PLX) versus Amylyx Pharmaceuticals (NASDAQ:AMLX)

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Protalix BioTherapeutics (NYSE:PLX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations for Amylyx Pharmaceuticals and Protalix BioTherapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1	0	8	2	3.00
Protalix BioTherapeutics	0	0	1	0	3.00

Amylyx Pharmaceuticals currently has a consensus target price of $36.50, suggesting a potential upside of 12.20%. Protalix BioTherapeutics has a consensus target price of $12.00, suggesting a potential upside of 340.37%. Given Protalix BioTherapeutics’ higher probable upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Amylyx Pharmaceuticals.

Profitability

This table compares Amylyx Pharmaceuticals and Protalix BioTherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

Insider and Institutional Ownership

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are owned by company insiders. Comparatively, 6.7% of Protalix BioTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Amylyx Pharmaceuticals has a beta of -0.13, indicating that its stock price is 113% less volatile than the S&P 500. Comparatively, Protalix BioTherapeutics has a beta of 0.02, indicating that its stock price is 98% less volatile than the S&P 500.

Earnings and Valuation

This table compares Amylyx Pharmaceuticals and Protalix BioTherapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37 million	41.48	-$144.74 million	($1.43)	-22.75
Protalix BioTherapeutics	$80.62 million	2.72	$8.31 million	$0.23	11.85

Protalix BioTherapeutics has lower revenue, but higher earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.